自进入临床以来，Ra-223积累了丰富的循证证据。整体而言，其临床应用是逐渐由后线治疗向早期治疗迈进，并在联合治疗策略中展现出令人振奋的疗效潜力。本次ESMO公布的RAPSON研究结果为早期启动Ra-223提供了新的证据，更重要的是为患者提供了更佳的 ...

Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.

Adding radium-223 to treatment with enzalutamide and a bone-protecting agent improved rPFS and OS in patients with mCRPC and ...

This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more ...

Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

2024年欧洲肿瘤内科学会年会（2024 ESMO）将于当地时间2024年9月13日至17日在西班牙巴塞罗那正式召开。一直以来，最新突破性摘要（LBA，Late Breaking Abstracts）都是年会中备受瞩目的焦点。同时，鉴于前列腺癌是我国泌尿男生殖系统最常见的恶性肿瘤，本次ESMO大会公布的前列腺癌重磅进展对于我国前列腺癌诊疗实践具有重要参考价值。

Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate ...

PEACE-3 trial results reveal that Enzalutamide combined with Radium-223 improves survival outcomes in prostate cancer ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Men with castration-resistant prostate cancer (CRPC) and asymptomatic or mildly symptomatic bone metastases lived ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

A wide selection of therapies are available to treat advanced prostate cancer, but the optimal treatment strategy is unknown.

作为消费角度来说，我们希望越多的品牌越好，因为这样的话行业竞争就越激烈，而且还可以选择到更多的机型，对我们作为消费者是有利的一面。而热门的品牌由于品牌效应所以一般价格相对会高一点，不太知名的品牌，要占据市场份额就不得不提升性价比，同等的价格性能配置等 ...